title: ALLERGIC REACTION UPON INTRAVITREAL ADMINISTRATION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS.
abstract: OBJECTIVE
  To describe the patient's allergic response to anti-vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization.
  
  
  METHODS
  Clinical case report.
  
  
  RESULTS
  Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept.
  
  
  CONCLUSIONS
  Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.
authors.affiliation: Rocky Vista University College of Osteopathic Medicine, Parker, Colorado.
authors.forename: Gavin G
authors.initials: GG
authors.lastname: Meredith
authors.affiliation: University of Colorado School of Medicine, Aurora, Colorado.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Schkade
authors.affiliation: Rocky Vista University College of Osteopathic Medicine, Parker, Colorado.|Colorado Retina Associates, PC, Denver, Colorado.
authors.forename: Brian C
authors.initials: BC
authors.lastname: Joondeph
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000068258:Bevacizumab / Q000009:adverse effects*; D020256:Choroidal Neovascularization / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000209:etiology*; D004417:Dyspnea / Q000139:chemically induced; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008875:Middle Aged; D000069579:Ranibizumab / Q000009:adverse effects*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab